Developing Functional Monoclonal Antibodies for Beta-3 Adrenergic Receptor
Poster Sep 10, 2014
Miao Tan and Helena Mancebo
G protein-coupled receptors (GPCRs), one of the most commonly used and successful targets for drugs, are a large family of multi-transmembrane proteins and an important class of receptors. Over 40% of all modern medicines interact with this protein group. These cell surface receptors are acted on by a wide variety of ligands, including small molecules and soluble proteins. Monoclonal antibody (mAb) therapy has major advantages over small molecule therapy in that mAbs are more selective and therefore tend to have fewer non-specic or o-target toxicity issues, while having a longer duration of action than small molecule drugs. Unfortunately, it is extremely dicult to create antibodies against GPCRs using traditional approaches, especially for clinical applications. Multispan combines its proprietary immunization technology using its patented GPCR high expression system and in-depth expertise in developing well-designed and validated GPCR functional assays to select mAb leads that perturb disease-relevant signaling pathways. In this poster, we detail the development of Beta-3 adrenergic receptor (β3-AR) mAbs. Our preliminary data showed that several mAb clones specically bound to the receptor while increasing the receptor function by acting as agonists.
Genome-wide association studies (GWAS) have identified more than 100 genetic loci associated with type 2 diabetes. The majority of these are located in the intergenic or intragenic regions suggesting that the implicated variants may alter chromatin conformation. This, in turn, is likely to influence the expression of nearby or more remotely located genes to alter beta cell function. At present, however, detailed molecular and functional analyses are still lacking for most of these variants. We recently analysed one of these loci and mapped five causal variants in an islet-specific enhancer cluster within the STARD10 gene locus. Here, we aimed to understand how these causal variants influence b-cell function by alteration of the chromatin structure of enhancer clusterREAD MORE
Human papillomavirus (HPV) vaccine rates continue to be low in the United States. Young women ages 18-26 years are eligible for catch-up vaccination but previous research shows that relationships status and percieved risk may be barriers to HPV vaccination. The purpose of this quantitative study was to assess the association between relationship status and perceived risk for HPV among young adult women.READ MORE
This abstract discusses three cases of pediatric heart transplant patients who suffered from parvovirus (B19) infection. Of these patients, two ( B & C) responded well to standard intravenous Ig therapy. Patient A however, did not respond to standard treatment and was begun on subcutaneous Ig, which effectively diminished his viral load. Thus, subcutaneous Ig infusions might serve as a second line treatment for transplant patients with parvovirus who do not respond well to the standard approach.READ MORE